New Phase 3 data demonstrate superiority of TREMFYA ® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news